Multi-Modal Electrotherapy Apparatus for Cardiac-Safe Defibrillation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing defibrillation devices face challenges in safely and effectively incorporating medium voltage therapy (MVT) due to differences in energy and waveform characteristics between MVT and defibrillation, which can lead to harmful outcomes when used on hearts in prolonged ventricular fibrillation, and there is a need to differentiate between ventricular and atrial fibrillation to ensure appropriate treatment.
Innovation Solution
A multi-modal electrotherapy apparatus that directs MVT and defibrillation therapies along different vectors, uses pulse shaping circuitry to generate biphasic waveforms, and incorporates atrial fibrillation discriminators to withhold MVT unless there is high confidence in ventricular fibrillation, ensuring safe and effective treatment by prioritizing cardiac perfusion and rhythm restoration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If medium voltage therapy (MVT) is delivered to treat ventricular fibrillation, then cardiac perfusion is improved, but harmful rhythms such as asystole or EMD may be induced in prolonged VF conditions
Solution Approach 1:
The patent segments the treatment approach by first delivering MVT to improve cardiac perfusion, then waiting for a predetermined period before delivering defibrillation. This temporal segmentation allows the heart to recover from prolonged VF before receiving the high-energy defibrillation shock, reducing the risk of inducing harmful rhythms while maintaining the perfusion benefits of MVT.
Solution Approach 2:
The patent applies MVT as a preliminary action before defibrillation to restore cardiac perfusion and oxygenation. This preliminary treatment prepares the heart for subsequent defibrillation by improving tissue oxygen levels and mechanical function, thereby reducing the likelihood of harmful outcomes when defibrillation is eventually delivered.
2Device complexity
If MVT and defibrillation are delivered using the same electrodes, then device complexity is reduced, but the risk of inducing harmful rhythms increases in prolonged VF
Solution Approach 1:
The patent segments the electrode usage by designating specific electrodes for MVT delivery and different electrodes for defibrillation delivery. This spatial segmentation ensures that MVT is delivered through electrodes that do not directly stimulate the ventricles in a way that could trigger harmful rhythms, while defibrillation uses electrodes optimized for terminating VF.
Solution Approach 2:
The patent applies local quality by using different electrode configurations for different therapeutic purposes. MVT electrodes are positioned to optimize perfusion without direct ventricular stimulation, while defibrillation electrodes are positioned for maximum efficacy in terminating VF. This localized optimization allows each electrode set to perform its specific function with minimal adverse effects.
3Productivity
If MVT is delivered without differentiating between ventricular and atrial fibrillation, then treatment responsiveness is improved, but inappropriate treatment may be delivered
Solution Approach 1:
The patent incorporates feedback mechanisms through atrial fibrillation discriminators that continuously monitor cardiac electrical activity and provide information about the type of arrhythmia present. This feedback allows the device to distinguish between AF and VF and automatically adjust the treatment algorithm to deliver appropriate therapy only for confirmed VF, preventing inappropriate MVT delivery for AF.
Solution Approach 2:
The patent replaces manual differentiation and treatment selection with an automated electronic discrimination system. The atrial fibrillation discriminators use signal processing and analysis algorithms to automatically identify VF versus AF, eliminating the need for manual assessment and ensuring consistent, accurate treatment decisions based on the detected arrhythmia type.
Data Source
AI summary
A multi-modal electrotherapy apparatus including circuitry for administering defibrillation therapy and for administering medium voltage therapy (MVT) adapted to reduce the side effects of MVT. The electrotherapy apparatus is configured to selectively deliver MVT to vectors not involving the ventricles and defibrillation therapy to vectors involving the ventricles. The apparatus can use biphasic waveforms configured to avoid capture of cardiac cells during MVT. The electrotherapy apparatus can minimize the risk of applying MVT at inappropriate times, such as during atrial fibrillation or where conventional ventricular tachycardia or ventricular fibrillation therapy is more appropriate.